Browse News
Filter News
Found 286 articles
-
bit.bio Expands Its Portfolio With Three New Human Cell Products for Research and Drug Discovery in Neurodegenerative and Neurological Diseases
11/23/2022
Cell coding company bit.bio announces three additions to its product portfolio: ioGlutamatergic Neurons MAPT N279K and ioGlutamatergic Neurons MAPT P301S disease models, and early access to its ioGABAergic Neurons.
-
New Movers & Shakers took over the roles of chief executive officer, chief financial officer, chief medical officer and more at companies including Scenic Biotech, Biofrontera and X4 Pharmaceuticals.
-
Triumvira Immunologics Appoints Life Sciences Industry Leader Robert Williamson as President and Chief Business Officer
10/25/2022
Triumvira Immunologics today announced the appointment of Robert Williamson as President and Chief Business Officer.
-
bit.bio Adds Two New Human Cell Products to Address the Translation Gap and Accelerate Research and Drug Discovery for Neurodegenerative Disease
9/29/2022
Cell coding company bit.bio has announced an expansion to its product portfolio - ioGlutamatergic Neurons TDP-43M337V disease model and early access to its ioMicroglia cell product.
-
Chemomab Therapeutics Appoints Jill M. Quigley, JD, to Its Board of Directors
6/21/2022
Ms. Quigley's Broad Biotechnology Industry Experience Encompasses Leadership Positions in Executive Management, Operations and Legal Affairs.
-
bit.bio’s New Huntington’s Disease Human Cell Model Set to Accelerate Drug Discovery and Screening
5/9/2022
bit.bio, a synthetic biology company working on developing and providing every human cell type at scale, with the aim of transforming the research and medicine landscape, launch their ioGlutamatergic Neurons HTT50CAG/WT cells to advance research and accelerate drug discovery for Huntington’s disease.
-
OncoMyx Appoints Robert Williamson Chief Business and Chief Financial Officer
3/2/2022
OncoMyx Therapeutics, a privately-held oncolytic virus immunotherapy company, today announced the appointment of Robert Williamson as Chief Business and Chief Financial Officer.
-
bit.bio Raises in Excess of $100 Million in First Close of Series B Financing
11/5/2021
Human cell coding company bit.bio announces the first close of their Series B financing of $103 million.
-
bit.bio expands Board of Directors with the Appointment of Entrepreneurs and a Nobel Laureate
10/28/2021
Today bit.bio welcomes three new members to its board of directors, who bring their respective experience of turning world class science into new industries and company growth.
-
BioSpace Movers & Shakers, June 11
6/11/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Intercept Appoints M. Michelle Berrey, M.D., M.P.H., as President of Research & Development and Chief Medical Officer
6/9/2021
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced the appointment of M. Michelle Berrey, M.D., M.P.H., as President of Research & Development and Chief Medical Officer.
-
BioSpace Movers & Shakers, Feb. 12
2/12/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Antios Therapeutics Appoints Patrick T. Higgins to Board of Directors
2/11/2021
Antios Therapeutics, Inc. (“Antios”) today announced the appointment of Patrick T. Higgins to the company’s board of directors. Mr. Higgins is a highly accomplished biopharmaceutical executive with more than two decades of experience leading companies in the development of therapies to treat infectious diseases
-
BioTheryX Appoints Robert F. Williamson, III as President and Chief Executive Officer
1/7/2021
BioTheryX, Inc., a clinical-stage company focused on degrading proteins to create life-saving medicines, today announced the appointment of experienced biotechnology leader Robert F. Williamson, III as President and Chief Executive Officer and a member of the BioTheryX Board of Directors.
-
Terns Appoints Three New Independent Directors to its Board
1/5/2021
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non- alcoholic steatohepatitis (NASH) and other chronic liver diseases, today announced the addition of three industry leaders as independent members of its board
-
Noveome Biotherapeutics, Inc. Announces New Appointments to its Board of Directors
10/22/2020
Noveome Biotherapeutics, Inc ., a clinical stage biopharmaceutical company focused on developing next-generation biologics for the restoration of cellular integrity of damaged tissues, has appointed M. Michelle Berrey, M.D., M.P.H. and Annamaria T. Kausz, M.D., M.S. as members of the company’s Board of Directors. “We are delighted to welcome Drs. Berrey and Kausz to our Board of Directors. Each brings a wealth of e
-
IN8bio Appoints Alan S. Roemer as ChairmanFounding Leadership Team Member of Pharmasset, Roivant and Axovant Who Brings Extensive Life Sciences Experience
10/7/2020
IN8bio, Inc., a clinical-stage biotechnology company focused on developing innovative allogeneic, autologous and genetically modified gamma-delta T cell therapies for the treatment of cancers, announced that Alan S. Roemer, MBA, MPH has been appointed Chairman of the Company’s Board of Directors.
-
A disappointed Merck said it was reviewing its options for a possible appeal, while a pleased Gilead said if an appeal came, it was confident a higher court would come to the same verdict as the federal appeals court.
-
Healthcare Payments Innovator MAPay Tackles Inefficiencies in Global Healthcare Transactions
4/2/2019
MAPay, LLC, a global healthcare technology firm, has deployed a transformational healthcare payment network with an expanding customer base, positive patenting positions, increasing revenues, and multiple industry stakeholder acceptance.
-
Durham, NC-based Precision BioSciences set its initial public offering (IPO) price at $16 per share, raising $126.4 million. It began trading today on the Nasdaq under the ticker symbol DTIL.